Skip to main content
Fig. 5 | Journal of Nanobiotechnology

Fig. 5

From: Biomimetic radiosensitizers unlock radiogenetics for local interstitial radiotherapy to activate systematic immune responses and resist tumor metastasis

Fig. 5

In vivo antitumor evaluations using 131I-MnO2-BSA on CT26-bearing mice model. a Digital photos of CT26 tumor-bearing mice that experienced different treatments at the end of experimental period, dose: 500 µCi; b Tumor growth curves of each mouse in different groups such as control, MnO2-BSA, free 131I and 131I-MnO2-BSA (dose: 500 µCi). c Time-dependent relative tumor volume variations of CT26 tumor-bearing mice experiencing corresponding treatments in different groups including control, MnO2-BSA, free 131I and 131I-MnO2-BSA (dose: 500 µCi), where tumor volumes were normalized to initial values (V/V0). Data are mean ± SD (n = 5). d ELISA-determined secretion levels of INF-γ and TNF-α in serum harvested from CT26-bearing mice that experienced different treatments with control, MnO2-BSA, free 131I and 131I-MnO2-BSA. e–l FCM patterns and corresponding statistical data of matured dendritic cells (CD80+CD86+) (e, f), CD3+CD8+CTLs (g, h), Tregs (i, j), CD206+CD11b+F4/80+(M2 macrophages) (k, l) in tumors harvested from CT26-bearing mice that experienced different treatments with G1–G4. Values are represented as mean ± SD (n = 3). G1–G4 represent Control, MnO2-BSA, free 131I and 131I-MnO2-BSA treatment, respectively. P values were calculated by ANOVA (**P < 0.01 and ***P < 0.001). Dose: 500 µCi

Back to article page